

authorized to charge any additionally required fee, or credit any overpayment in such fees, to Deposit Account No. 50-0320.

AMENDMENT

Please amend the application without prejudice, without admission, without surrender of subject matter, and without any intention of creating any estoppel as to equivalents as follows:

IN THE CLAIMS:

Please amend the claims without prejudice, without admission, without surrender of subject matter, and without any intention of creating any estoppel as to equivalents as follows:

48. The method according to claim 47, wherein the agent engages a receptor by direct engagement or indirect engagement.

52. The method according to claim 47, wherein the committed cells are human leukocytes, wherein the human leukocytes are found in peripheral blood, bone marrow, thymus, spleen or tonsil tissue, and wherein the leukocytes are selected from the group consisting of lymphocytes, monocytes, polymorphonuclear cells, eosinophils and basophils.

53. The method according to claim 48 wherein the CD45 low cells are Major Histocompatibility Complex (MHC) class I⁺ and/or MHC class II⁺ cells.

54. The method according to claim 47, wherein the receptor is an MHC class I antigen or an MHC class II antigen.

63. A method according to claim 47, wherein the agent is used in conjunction with a biological response modifier as defined herein.

Kindly add new claims 66-72, without prejudice, as follows:

--66. The method according to claim 47, wherein the committed cells are leukocyte progenitors found in bone marrow.

67. The method according to claim 47, wherein the committed cells are immature haematopoietic precursor cells or haematopoietic colony-forming cells found in bone marrow.